CTOs on the Move

ZielBio

www.zielbio.com

 
ZielBio is an early-stage biotechnology company that identifies novel high value disease targets and develops therapeutic interventions to improve patient outcomes. Our proprietary drug discovery platform Zielfind™ combines the power of functional, high throughput screening with large content data analytics to identify high value targets. We have a promising pipeline of therapies and targets, including lead compound ZB131, a proprietary humanized monoclonal antibody against cell surface plectin (CSP) a cancer target identified through Zielfind™.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.zielbio.com
  • 315 Old Ivy Way Suite 301
    Charlottesville, AB USA 22903
  • Phone: N/A

Executives

Name Title Contact Details

Funding

ZielBio raised $25.1M on 09/26/2019

Similar Companies

Geltor

Geltor is the bio-design company that makes the world`s most advanced proteins for consumers, with a focus on unique functionality and sustainability.

Cellino Biotech

Personalized regenerative medicines at scale.

Quellis Biosciences

Quellis was founded to deliver best-in-class therapies to patients suffering serious rare diseases – and underserved by current treatment options. The Company is based in Boston, and is led by partners from the biotech incubator Viridian LLC in collaboration with team at biotech accelerator Xontogeny LLC, and with funding from the Perceptive Xontogeny Venture Fund. The Quellis team has deep experience in mAb discovery and development, company creation, and private and public biotech investment. Our shared goal is to create meaningful medicines for every disease we target.

Notch Therapeutics

Notch is an immune cell therapy company developing a next-generation pipeline of off-the-shelf, universally compatible, genetically tailored T cell therapeutics derived from renewable stem cell sources for the treatment of high-impact diseases, with an initial focus on cancer.

F1 Oncology

We are harnessing the power of the immune system to target some of the most challenging solid tumor malignancies.